AA
SYRE icon

ALPS Advisors’s Spyre Therapeutics SYRE Stock Holding History

ALPS Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,939
Closed -$3.23M – 1213
2026
Q1 		$3.23M Buy
63,939
+231
+0.4% +$8.71K 0.02% 319
2025
Q4 		$2.09M Buy
+63,708
New +$1.66M 0.01% 386
2022
Q2 		– Sell
-2,029
Closed -$117K – 1086
2022
Q1 		$117K Sell
2,029
-254
-11% -$21.3K ﹤0.01% 822
2021
Q4 		$271K Buy
+2,283
New +$360K ﹤0.01% 847

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ALPS Advisors's SYRE Position: Q2 2026 in Review

ALPS Advisors sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 63,939 shares — an estimated $3.23M sold.

ALPS Advisors first reported a position in SYRE in Q4 2021 and held it in 4 quarters. The position peaked at $3.23M in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • ALPS Advisors reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 63,939 Spyre Therapeutics shares in Q2 2026, an estimated $3.23M.
  • ALPS Advisors first reported a position in Spyre Therapeutics in Q4 2021 and held it in 4 quarters.
  • ALPS Advisors's Spyre Therapeutics position peaked at $3.23M in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.